Thymosin alpha-1
A 28-amino-acid peptide derived from prothymosin α with broad immune-modulatory effects.
How it works
Activates Toll-like receptors (TLR9/2), boosts Th1 immunity, enhances dendritic-cell maturation, and supports T-cell differentiation.
Reported benefits
- Adjunctive use in chronic hepatitis B and C protocols (approved in some countries)
- Enhanced vaccine responses in immunocompromised cohorts
- Studied in sepsis and severe respiratory infections
Dosage & administration
Research range: 1.6 mg subcutaneously twice weekly.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
Thymosin α-1 in severe sepsis
Critical Care · 2013
Reduced 28-day mortality vs control in trial cohort.
Safety & warnings
- Generally well tolerated; injection-site reactions possible
- Use under medical supervision in autoimmune disease
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
5 mg
TA5
Box of 10 · $300
Single vial · $600
10 mg
TA10
Box of 10 · $504
Single vial · $1,008